Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial

02/24/2022
by   Lisa V. Hampson, et al.
0

Single-arm trials (SATs) may be used to support regulatory submissions in settings where there is a high unmet medical need and highly promising early efficacy data undermine the equipoise needed for randomization. In this context, patient-level real-world data (RWD) may be used to create an external control arm (ECA) to contextualize the SAT results. However, naive comparisons of the SAT with its ECA will yield biased estimates of causal effects if groups are imbalanced with regards to (un)measured prognostic factors. Several methods are available to adjust for measured confounding, but the interpretation of such analyses is challenging unless the causal question of interest is clearly defined, and the estimator is aligned with the estimand. Additional complications arise when patients in the ECA are eligible for the SAT at multiple timepoints. In this paper, we use a case-study of a pivotal SAT of a novel CAR-T therapy for heavily pre-treated patients with follicular lymphoma to illustrate how a combination of the target trial and the ICH E9(R1) estimand frameworks can be used to define the target estimand and avoid common methodological pitfalls related to the design of the ECA and comparisons with the SAT. We also propose an approach to address the challenge of how to define an appropriate time zero for external controls who meet the SAT inclusion/exclusion criteria at several timepoints. Use of the target trial and estimand frameworks facilitates discussions amongst internal and external stakeholders, as well as an early assessment of the adequacy of the available RWD.

READ FULL TEXT

page 26

page 28

research
10/07/2021

A meta-analytic framework to adjust for bias in external control studies

While randomized controlled trials (RCTs) are the gold standard for esti...
research
06/20/2022

How to improve the quality of comparisons using external control cohorts in single-arm clinical trials?

PURPOSE Providing rapid answers and early acces to patients to innovativ...
research
07/11/2023

Considerations for Master Protocols Using External Controls

There has been an increasing use of master protocols in oncology clinica...
research
08/16/2021

Augmenting control arms with Real-World Data for cancer trials: Hybrid control arm methods and considerations

Randomized controlled trials (RCTs) are the gold standard for assessing ...
research
06/02/2023

Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access

The incorporation of "real-world data" to supplement the analysis of tri...
research
10/01/2020

A note on the amount of information borrowed from external data in hybrid controlled trials with time-to-event outcomes

In situations where it is difficult to enroll patients in randomized con...

Please sign up or login with your details

Forgot password? Click here to reset